EGFR and cancer: Accumulating evidence suggests that small subpopulations of cancer cells can survive strong EGFR inhibition by entering a DTP state, which could allow the emergence of heterogeneous EGFR TKI resistance mechanisms in EGFR-mutant lung cancers (Sharma et al., 2010; Ramirez et al., 2016).